Cost & Affordability
Expert articles and analysis related to cost & affordability.
AI Summary — Last 24 Hours
CMS’s Medicare Advantage/Part D policy agenda is putting affordability pressure on plans and downstream VBC partners: the CY2027 MA and drug benefit rulemaking, drug price negotiation implementation, and stakeholder comments from AHA signal tighter scrutiny of benefit design, pharmacy economics, and provider reimbursement exposure under Medicare payment policy. At the same time, market actors are already adjusting—Aetna is cutting MA broker commissions for 2027 sales, while hospital and insurer stakeholders are pushing broader value-based care and chronic-condition management as cost-control strategies amid rising total cost of care pressures (Aetna MA commissions, [AHA on CMS drug pricing rule](https://news.google.com/rss/articles/CBMivAFBVV95cUxPN
Related Articles
Beyond Point Solutions: Chronic Condition Support for Total Cost of Care
Beyond Point Solutions: Chronic Condition Support for Total Cost of Care AHIP
As healthcare costs weigh on patients, states could play a bigger role, report finds
As healthcare costs weigh on patients, states could play a bigger role, report finds Fierce Healthcare
5 forces driving health insurance costs up in 2027
5 forces driving health insurance costs up in 2027 Becker's Payer Issues
How Out-of-Pocket Spending Caps in Traditional Medicare Could Affect Beneficiary and Program Spending
How Out-of-Pocket Spending Caps in Traditional Medicare Could Affect Beneficiary and Program Spending Urban Institute
Beyond Compliance: Rethinking No Surprises Act strategy
Beyond Compliance: Rethinking No Surprises Act strategy Fierce Healthcare
Hospital group pushes value-based care to curb health costs
Hospital group pushes value-based care to curb health costs BenefitsPRO
Policy Options to Lower Drug Prices
Policy Options to Lower Drug Prices Margolis Institute for Health Policy
Lawmakers Introduce Bill To Add Home Care Benefit To Medicare
MFP Effectuation and the SDRA: The Possibility of ASP Spirals in Competitive Drug Classes[
The real cost ASC leaders forget to calculate
The real cost ASC leaders forget to calculate Becker's ASC